Chronic Adolescent Exposure to Delta-9-Tetrahydrocannabinol in COMT Mutant Mice: Impact on Indices of Dopaminergic, Endocannabinoid and GABAergic Pathways
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Cannabis use confers a two-fold increase in risk for psychosis, with adolescent use conferring an even greater risk. A high-low activity polymorphism in catechol-O-methyltransferase (COMT), a gene encoding the COMT enzyme involved in dopamine clearance in the brain, may interact with adolescent cannabis exposure to increase risk for schizophrenia. The impact of such an interaction on central neurotransmitter pathways implicated in schizophrenia is unknown. Male mice with knockout of the COMT gene were treated chronically with delta-9-tetrahydrocannabinol (THC) during adolescence (postnatal day 32-52). We measured the size and density of GABAergic cells and the protein expression of cannabinoid receptor 1 (CB1R) in the prefrontal cortex (PFC) and hippocampus (HPC) in knockout mice relative to heterozygous mutants and wild-type controls. Size and density of dopaminergic neurons was also assessed in the ventral tegmental area (VTA) across the genotypes. COMT genotype × THC treatment interactions were observed for: (1) dopaminergic cell size in the VTA, (2) CB1R protein expression in the HPC, and (3) parvalbumin (PV) cell size in the PFC. No effects of adolescent THC treatment were observed for PV and dopaminergic cell density across the COMT genotypes. COMT genotype modulates the effects of chronic THC administration during adolescence on indices of neurotransmitter function in the brain. These findings illuminate how COMT deletion and adolescent cannabis use can interact to modulate the function of neurotransmitters systems implicated in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 3×
“Our GABAergic findings in the COMT mutant mouse are interesting, given that most of the effects of the endocannabinoid system on dopaminergic neurotransmission are GABA- and/or glutamate-mediated (Herkenham et al, 1990; Mailleux and Vanderhaeghen, 1992; Tsou et al, 1998).”
BackgroundCannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224 · cited 3×
“…is highest when cannabis is consumed during adolescence (Arseneault et al, 2002; Caspi et al, 2005; Konings et al, 2008; McGrath et al, 2010; Moore et al, 2007), possibly because the brain is still developing (Ehrenreich et al, 1999; Pistis et al, 2004; Pope et al, 2003; Schneider and Koch,…”
BackgroundSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y.-M., Szumlanski, C. L., & Weinshilboum, R. M. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00007 · Cited by 1,788
Chen, J., Lipska, B. K., Halim, N., Ma, Q. D., Matsumoto, M., Melhem, S., Kolachana, B. S., Hyde, T. M., Herman, M. M., Apud, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/425589 · Cited by 1,675
The principal features and mechanisms of dopamine modulation in the prefrontal cortex
Seamans, J. K., & Yang, C. R. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.006 · Cited by 1,592 · cited 7×
“…and cortical dopaminergic activity involving the COMT gene, whereby a narrow range of dopamine can benefit PFC function and either insufficient or excessive dopamine can impair cognitive function (Castner et al, 2000; Goldman-Rakic et al, 2000; Seamans and Yang, 2004; Tunbridge et al, 2006).”
BackgroundInfluentialImmunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586 · cited 3×
“Our GABAergic findings in the COMT mutant mouse are interesting, given that most of the effects of the endocannabinoid system on dopaminergic neurotransmission are GABA- and/or glutamate-mediated (Herkenham et al, 1990; Mailleux and Vanderhaeghen, 1992; Tsou et al, 1998).”
BackgroundThe environment and schizophrenia
van Os, J., Kenis, G., & Rutten, B. P. F. (2010) · Nature · doi:10.1038/nature09563 · Cited by 1,572 · cited 2×
“Reports have shown that a functional polymorphism in the COMT gene can moderate the association between cannabis use and psychosis (Caspi et al, 2005; Harrison and Weinberger, 2005; Tunbridge et al, 2006; van Os et al, 2010), but not all studies support such associations (Zammit et al, 2011).”
BackgroundCaspi, A., Moffitt, T. E., Cannon, M., McClay, J., Murray, R., Harrington, H., Taylor, A., Arseneault, L., Williams, B., Braithwaite, A., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.026 · Cited by 1,409
Self-citationCannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002) · BMJ · doi:10.1136/bmj.325.7374.1212 · Cited by 1,399 · cited 2×
“…Henquet et al, 2005; Moore et al, 2007), and the risk of developing psychotic symptoms is highest when cannabis is consumed during adolescence (Arseneault et al, 2002; Caspi et al, 2005; Konings et al, 2008; McGrath et al, 2010; Moore et al, 2007), possibly because the brain is still…”
BackgroundSelf-citation
Cited by
Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 517
The effects of Δ9-tetrahydrocannabinol on the dopamine system
Bloomfield, M. A. P., Ashok, A. H., Volkow, N. D., & Howes, O. D. (2016) · Nature · doi:10.1038/nature20153 · Cited by 373
One Is Not Enough: Understanding and Modeling Polysubstance Use
Crummy, E. A., O’Neal, T. J., Baskin, B. M., & Ferguson, S. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00569 · Cited by 351
Adolescent neurodevelopment and substance use: receptor expression and behavioral consequences
Thorpe, H. H. A., Hamidullah, S., Jenkins, B. W., & Khokhar, J. Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107431 · Cited by 97
Renard, J., Rushlow, W. J., & Laviolette, S. R. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00281 · Cited by 62
COMT val158met and 5-HTTLPR Genetic Polymorphisms Moderate Executive Control in Cannabis Users
Verdejo-García, A., Fagundo, A. B., Cuenca, A., Rodriguez, J., Cuyás, E., Langohr, K., de Sola Llopis, S., Civit, E., Farré, M., Peña-Casanova, J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.59 · Cited by 53
Morishita, H., Kundakovic, M., Bicks, L., Mitchell, A., & Akbarian, S. (2015) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2015.03.005 · Cited by 42
Metadata
- Authors
- Behan, Á. T., Hryniewiecka, M., O'Tuathaigh, C. M. P., Kinsella, A., Cannon, M., Karayiorgou, M., Gogos, J. A., Waddington, J. L., & Cotter, D. R.
- Venue
- Neuropsychopharmacology
- Published
- 2012-03-21
- Volume
- 37
- Issue
- 7
- Pages
- 1773-1783
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1989764163
- Cited by
- 69
- References
- 25
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.